New York (March 3rd, 2013) - MultiCell Technologies, Inc. (OTCQB: MCET) Files SEC form 10-K, Annual Report.
Total revenue for the fiscal years ended November 30, 2012 and November 30, 2011 was $49,318. All of the revenue for the fiscal years ended November 30, 2012 and 2011 is from the amortization of deferred license revenue under agreements with Corning and Pfizer.
Management states “Following the formation of MCTI during September 2005 and the recent in-licensing of drug candidates, we are pursuing research and development of therapeutics. Historically, we have specialized in developing primary liver cell immortalization technologies to produce cell-based assay systems for use in drug discovery. We seek to become an integrated biopharmaceutical company that will use its immune system modulation technologies to discover, develop and commercialize new therapeutics itself and with strategic partners.”
Find out more on MCET by getting the free and full daily trend analysis report here: http://www.wallstreetreport.net/market-scan/?symbol=MCET
Federal National Mortgage Association (OTCQB: FNMA) January 2013 Monthly Summary is now available. The monthly summary report contains information about Fannie Mae's monthly and year-to-date activities for our gross mortgage portfolio, mortgage-backed securities and other guarantees, interest rate risk measures, serious delinquency rates, and loan modifications.
Federal National Mortgage Association (Fannie Mae) provides liquidity and stability support in the secondary mortgage market in the United States. The company securitizes mortgage loans originated by lenders in the primary mortgage market into Fannie Mae mortgage-backed securities (Fannie Mae MBS). It operates in three segments: Single-Family Credit Guaranty, Multifamily, and Capital Markets.
Get the daily trend analysis reports on FNMA here: http://www.wallstreetreport.net/market-scan/?symbol=FNMA
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit: www.wallstreetreport.net/disclaimer-2/
WALL STREET REPORT
Leave a comment...